Cell Line Development Market Analysis, Size, Segment To 2022 by Grand View Research, Inc. by Dhanashree

Cell Line Development Market To Reach $6.24 Billion By 2022

Global cell line development market size is expected to reach USD 6.24 billion by 2022, according to a new report by Grand View Research, Inc. The Increasing demand for monoclonal antibodies and patent expiration of blockbuster biologics are expected to drive the cell line development industry over the forecast period. Increasing prevalence of autoimmune diseases and cancer are likely to increase the demand for accurate and cost effective treatment options which is expected to render a positive impact on market growth. In addition, improving healthcare infrastructure, economic development and favorable government initiatives promoting the growth of the biotechnology industry are factors contributing towards the growth of the cell line development market. Ongoing R&D for stable & authentic cell lines and the introduction of technologically advanced processes such as single use bioreactor and micro bioreactor for large scale bioproduction are further expected to provide this market with lucrative future growth opportunities. View summary of this report @ http://www.grandviewresearch.com/industry-analysis/cellline-development-market

U.S. cell line development market, by type, 2012-2022 (USD Million)

Table of Content Chapter 1. Methodology and Scope 1.1. Research methodology 1.2. Research scope &assumption 1.3. List of data sources Chapter 2. Executive Summary 2.1. Cell Line Development- Industry Snapshot and Key Buying Criteria, 2012 2022 Chapter 3. Cell Line Development Industry Outlook 3.1. Cell line development market segmentation 3.2. Cell line development market size and growth prospects, 2012 - 2022 3.3. Cell line development market dynamics 3.3.1. Market driver analysis 3.3.2. Market restraint analysis 3.4. Key opportunities prioritized 3.5. Industry Analysis - Porter's 3.6. Cell line development competitive landscape, 2014

3.6.1. Company market share analysis, 2014 3.6.2. Market position analysis, 2014 (based on products, regional presence and strategic initiatives) 3.7. Cell line development market PESTEL analysis, 2014 Chapter 4. Cell Line Development Product Outlook 4.1. Cell line development market share by product, 2014 & 2022 4.2. Reagents and media 4.2.1. Reagents and media market estimates and forecasts, 2012 – 2022 (USD million) 4.3. Equipments 4.3.1. Equipments market estimates and forecasts, 2012 – 2022 (USD million) 4.3.2. Incubators 4.3.2.1. Incubators market estimates and forecasts, 2012 – 2022 (USD million) 4.3.3. Centrifuges 4.3.3.1. Centrifuges market estimates and forecasts, 2012 – 2022 (USD million) 4.3.4. Bioreactors 4.3.4.1. Bioreactors market estimates and forecasts, 2012 – 2022 (USD million) 4.3.5. Storage equipment 4.3.5.1. Storage equipment market estimates and forecasts, 2012 – 2022 (USD million) 4.3.6. Microscopes 4.3.6.1. Microscopes market estimates and forecasts, 2012 – 2022 (USD million) 4.4. Accessories and consumables 4.4.1. Accessories and consumables market estimates and forecasts, 2012 – 2022 (USD million) Chapter 5. Cell Line Development Source Outlook 5.1. Cell line development market share by source, 2014 & 2022 5.2. Mammalian 5.2.1. Mammalian market estimates and forecasts, 2012 – 2022 (USD million) 5.3. Non mammalian 5.3.1. Non mammalian market estimates and forecasts, 2012 – 2022 (USD million) 5.3.2. Insects 5.3.2.1. Insects market estimates and forecasts, 2012 – 2022 (USD million) 5.3.3. Amphibians 5.3.3.1. Amphibians market estimates and forecasts, 2012 – 2022 (USD million) Chapter 6. Cell Line Development Type Of Cell Lines Outlook 6.1. Cell line development market share, by type of cell lines, 2014 & 2022

6.2. Recombinant cell lines 6.2.1. Recombinant cell lines market estimates and forecasts, 2012 – 2022 (USD million) 6.3. Hybridomas 6.3.1. Hybridomas market estimates and forecasts, 2012 – 2022 (USD million) 6.4. Continuous cell lines 6.3.1. Continuous cell lines market estimates and forecasts, 2012 – 2022 (USD million) 6.5. Primary cell lines 6.5.1. Primary cell lines market estimates and forecasts, 2012 – 2022 (USD million) Chapter 7. Cell Line Development Application Outlook 7.1. Cell line development market share, by application, 2014 & 2022 7.2. Bioproduction 7.2.1. Bioproduction market estimates and forecasts, 2012 – 2022 (USD million) 7.3. Drug discovery 7.3.1. Drug discovery market estimates and forecasts, 2012 – 2022 (USD million) 7.4. Toxicity testing 7.4.1. Toxicity testing market estimates and forecasts, 2012 – 2022 (USD million) 7.5. Vaccines 7.5.1. Vaccines market estimates and forecasts, 2012 – 2022 (USD million) 7.6. Tissue engineering 7.6.1. Tissue engineering market estimates and forecasts, 2012 – 2022 (USD million) 7.7. Others 7.7.1. Others market estimates and forecasts, 2012 – 2022 (USD million) Chapter 8. Cell Line Development Regional Outlook 8.1. Cell line development market share, by region, 2014 & 2022 8.2. North America 8.2.1. North America market, by product, 2012 – 2022 (USD million) 8.2.1.1. U.S. 8.2.1.1.1. Market estimates and forecasts, 2014 - 2022 8.2.1.2. Canada 8.2.1.2.1. Market estimates and forecasts, 2014 - 2022 8.2.2. North America market, by source, 2012 – 2022 (USD million) 8.2.2.1. U.S. 8.2.2.1.1. Market estimates and forecasts, 2014 - 2022 8.2.2.2. Canada

8.2.2.2.1. Market estimates and forecasts, 2014 – 2022 8.2.3. North America market, by type of cell lines, 2012 – 2022 (USD million) 8.2.3.1. U.S. 8.2.3.1.1. Market estimates and forecasts, 2014 - 2022 8.2.3.2. Canada 8.2.3.2.1. Market estimates and forecasts, 2014 – 2022 8.2.4. North America market, by application, 2012 – 2022 (USD million) 8.2.4.1. U.S. 8.2.4.1.1. Market estimates and forecasts, 2014 - 2022 8.2.4.2. Canada 8.2.4.2.1. Market estimates and forecasts, 2014 - 2022 8.3. Europe 8.3.1. Europe market, by product, 2012 – 2022 (USD million) 8.3.1.1. UK 8.3.1.1.1. Market estimates and forecasts, 2014 - 2022 8.3.1.2. Germany 8.3.1.2.1. Market estimates and forecasts, 2014 - 2022 8.3.2. Europe market, by source, 2012 – 2022 (USD million) 8.3.2.1. UK 8.3.2.1.1. Market estimates and forecasts, 2014 - 2022 8.3.2.2. Germany 8.3.2.2.1. Market estimates and forecasts, 2014 – 2022 8.3.3. Europe market, by type of cell lines, 2012 – 2022 (USD million) 8.3.3.1. UK 8.3.3.1.1. Market estimates and forecasts, 2014 - 2022 8.3.3.2. Germany 8.3.3.2.1. Market estimates and forecasts, 2014 – 2022 8.3.4. Europe market, by application, 2012 – 2022 (USD million) 8.3.4.1. UK 8.3.4.1.1. Market estimates and forecasts, 2014 - 2022 8.3.4.2. Germany 8.3.4.2.1. Market estimates and forecasts, 2014 – 2022 8.4. Asia Pacific 8.4.1. Asia Pacific market, by product, 2012 – 2022 (USD million) 8.4.1.1. Japan 8.4.1.1.1. Market estimates and forecasts, 2014 - 2022 8.4.1.2. China 8.4.1.2.1. Market estimates and forecasts, 2014 – 2022

8.4.1.3. India 8.4.1.3.1. Market estimates and forecasts, 2014 – 2022 8.4.2. Asia Pacific market, by source, 2012 – 2022 (USD million) 8.4.2.1. Japan 8.4.2.1.1. Market estimates and forecasts, 2014 - 2022 8.4.2.2. China 8.4.2.2.1. Market estimates and forecasts, 2014 – 2022 8.4.2.3. India 8.4.2.3.1. Market estimates and forecasts, 2014 – 2022 8.4.3. Asia Pacific market, by type of cell lines, 2012 – 2022 (USD million) 8.4.3.1. Japan 8.4.3.1.1. Market estimates and forecasts, 2014 - 2022 8.4.3.2. China 8.4.3.2.1. Market estimates and forecasts, 2014 – 2022 8.4.3.3. India 8.4.3.3.1. Market estimates and forecasts, 2014 – 2022 8.4.4. Asia Pacific market,, by application, 2012 – 2022 (USD million) 8.4.4.1. Japan 8.4.4.1.1. Market estimates and forecasts, 2014 - 2022 8.4.4.2. China 8.4.4.2.1. Market estimates and forecasts, 2014 – 2022 8.4.4.3. India 8.4.4.3.1. Market estimates and forecasts, 2014 – 2022 8.5. Latin America 8.5.1. Latin America market, by product, 2012 – 2022 (USD million) 8.5.1.1. Mexico 8.5.1.1.1. Market estimates and forecasts, 2014 - 2022 8.5.1.2. Brazil 8.5.1.2.1. Market estimates and forecasts, 2014 - 2022 8.5.2. Latin America market, by source, 2012 – 2022 (USD million) 8.5.2.1. Mexico 8.5.2.1.1. Market estimates and forecasts, 2014 - 2022 8.5.2.2. Brazil 8.5.2.2.1. Market estimates and forecasts, 2014 – 2022 8.5.3. Latin America market, by type of cell lines, 2012 – 2022 (USD million) 8.5.3.1. Mexico 8.5.3.1.1. Market estimates and forecasts, 2014 - 2022 8.5.3.2. Brazil

8.5.3.2.1. Market estimates and forecasts, 2014 – 2022 8.5.4. Latin America market, by application, 2012 – 2022 (USD million) 8.5.4.1. Mexico 8.5.4.1.1. Market estimates and forecasts, 2014 - 2022 8.5.4.2. Brazil 8.5.4.2.1. Market estimates and forecasts, 2014 – 2022 8.6. MEA 8.6.1. MEA market, by product, 2012 – 2022 (USD million) 8.6.1.1. South Africa 8.6.1.1.1. Market estimates and forecasts, 2014 - 2022 8.6.2. MEA market, by source, 2012 – 2022 (USD million) 8.6.2.1. South Africa 8.6.2.1.1. Market estimates and forecasts, 2014 – 2022 8.6.3. MEA market, by type of cell lines, 2012 – 2022 (USD million) 8.6.3.1. South Africa 8.6.3.1.1. Market estimates and forecasts, 2014 – 2022 8.6.4. MEA market, by application, 2012 – 2022 (USD million) 8.6.4.1. South Africa 8.6.4.1.1. Market estimates and forecasts, 2014 – 2022 Chapter 9. Competitive Landscape 9.1. GE Healthcare 9.1.1. Company Overview 9.1.2. Financial Performance 9.1.3. Product Benchmarking 9.1.4. Strategic Initiatives 9.2. Thermo Fisher Scientific Inc. (Lifetechnologies) 9.2.1. Company Overview 9.2.2. Financial Performance 9.2.3. Product Benchmarking 9.2.4. Strategic Initiatives 9.3. European Collection of Cell Cultures 9.3.1. Company Overview 9.3.2. Financial Performance 9.3.3. Product Benchmarking 9.3.4. Strategic Initiatives 9.4. Lonza Group AG 9.4.1. Company Overview 9.4.2. Financial Performance

9.4.3. Product Benchmarking 9.4.4. Strategic Initiatives 9.5. Sigma Aldrich Corporation 9.5.1. Company Overview 9.5.2. Financial Performance 9.5.3. Product Benchmarking 9.5.4. Strategic Initiatives 9.6. WuXi AppTec 9.6.1. Company Overview 9.6.2. Financial Performance 9.6.3. Product Benchmarking 9.6.4. Strategic Initiatives 9.7. American Type Culture Collection 9.7.1. Company Overview 9.7.2. Financial Performance 9.7.3. Product Benchmarking 9.7.4. Strategic Initiatives 9.8. Sartorius AG 9.8.1. Company Overview 9.8.2. Financial Performance 9.8.3. Product Benchmarking 9.8.4. Strategic Initiatives 9.9. Corning Inc. 9.9.1. Company Overview 9.9.2. Financial Performance 9.9.3. Product Benchmarking 9.9.4. Strategic Initiatives 9.10. Selexis AG 9.10.1. Company Overview 9.10.2. Financial Performance 9.10.3. Product Benchmarking 9.10.4. Strategic Initiatives 9.11. Vista Biological Co 9.11.1. Company Overview 9.11.2. Financial Performance 9.11.3. Product Benchmarking 9.11.4. Strategic Initiatives 9.12. Eubiologics

9.12.1. Company Overview 9.12.2. Financial Performance 9.12.3. Product Benchmarking 9.12.4. Strategic Initiatives 9.13. Paragon Bioservices 9.13.1. Company Overview 9.13.2. Financial Performance 9.13.3. Product Benchmarking 9.13.4. Strategic Initiatives 9.14. Cobra 9.14.1. Company Overview 9.14.2. Financial Performance 9.14.3. Product Benchmarking 9.14.4. Strategic Initiatives 9.15. Gallus Biopharma 9.15.1. Company Overview 9.15.2. Financial Performance 9.15.3. Product Benchmarking 9.15.4. Strategic Initiatives 9.16. Samsung Biologic 9.16.1. Company Overview 9.16.2. Financial Performance 9.16.3. Product Benchmarking 9.16.4. Strategic Initiatives 9.17. Naeja 9.17.1. Company Overview 9.17.2. Financial Performance 9.17.3. Product Benchmarking 9.17.4. Strategic Initiatives 9.18. Aragen Bioscience 9.18.1. Company Overview 9.18.2. Financial Performance 9.18.3. Product Benchmarking 9.18.4. Strategic Initiatives 9.19. GVK BIO 9.19.1. Company Overview 9.19.2. Financial Performance 9.19.3. Product Benchmarking

9.19.4. Strategic Initiatives 9.20. PCT 9.20.1. Company Overview 9.20.2. Financial Performance 9.20.3. Product Benchmarking 9.20.4. Strategic Initiatives 9.21. Apath 9.21.1. Company Overview 9.21.2. Financial Performance 9.21.3. Product Benchmarking 9.21.4. Strategic Initiatives 9.22. Cell for cure 9.22.1. Company Overview 9.22.2. Financial Performance 9.22.3. Product Benchmarking 9.22.4. Strategic Initiatives 9.23. TRL 9.23.1. Company Overview 9.23.2. Financial Performance 9.23.3. Product Benchmarking 9.23.4. Strategic Initiatives 9.24. Episteme 9.24.1. Company Overview 9.24.2. Financial Performance 9.24.3. Product Benchmarking 9.24.4. Strategic Initiatives 9.25. Catalent 9.25.1. Company Overview 9.25.2. Financial Performance 9.25.3. Product Benchmarking 9.25.4. Strategic Initiatives 9.26. Bioceros 9.26.1. Company Overview 9.26.2. Financial Performance 9.26.3. Product Benchmarking 9.26.4. Strategic Initiatives 9.27. Antitope 9.27.1. Company Overview

9.27.2. Financial Performance 9.27.3. Product Benchmarking 9.27.4. Strategic Initiatives 9.28. Promocell 9.28.1. Company Overview 9.28.2. Financial Performance 9.28.3. Product Benchmarking 9.28.4. Strategic Initiatives 9.29. Cyagen 9.29.1. Company Overview 9.29.2. Financial Performance 9.29.3. Product Benchmarking 9.29.4. Strategic Initiatives

Browse full report @ http://www.grandviewresearch.com/industry-analysis/cell-linedevelopment-market

List of Tables TABLE 1 Cell Line Development - Industry Snapshot & Key Buying Criteria, 2012 - 2022 TABLE 2 Global cell line development market, by product, 2012 - 2022 (USD Million) TABLE 3 Global cell line development market, by source, 2012 - 2022 (USD Million) TABLE 4 Global cell line development market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 5 Global cell line development market, by application, 2012 - 2022 (USD Million) TABLE 6 Global cell line development market, by region, 2012 - 2022 (USD Million) TABLE 7 Cell line development - Key market driver analysis TABLE 8 Global cancer incidences, 2012 TABLE 9 North America cancer incidences in 2012 TABLE 10 Europe cancer incidences, 2012 TABLE 11 Asia cancer incidences, 2012 TABLE 12 Africa cancer incidences, 2012 TABLE 13 Australia and New Zealand cancer incidences in 2012 TABLE 14 Cell line development - Key market restraint analysis TABLE 15 North America market, by product, 2012 - 2022 (USD Million) TABLE 16 North America market, by equipment, 2012 - 2022 (USD Million) TABLE 17 North America cell line development market, by source, 2012 - 2022 (USD Million) TABLE 18 North America market, by non mammalian source, 2012 - 2022 (USD Million) TABLE 19 North America market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 20 North America market, by application, 2012 - 2022 (USD Million) TABLE 21 U.S. cell line development market, by product, 2012 - 2022 (USD Million)

TABLE 22 U.S cell line development market, by equipment, 2012 - 2022 (USD Million) TABLE 23 U.S. cell line development market, by source, 2012 - 2022 (USD Million) TABLE 24 U.S. market, by non mammalian source, 2012 - 2022 (USD Million) TABLE 25 U.S. market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 26 U.S. market, by application, 2012 - 2022 (USD Million) TABLE 27 Canada market, by product, 2012 - 2022 (USD Million) TABLE 28 Canada market, by equipment, 2012 - 2022 (USD Million) TABLE 29 Canada market, by source, 2012 - 2022 (USD Million) TABLE 30 Canada market, by non mammalian source, 2012 - 2022 (USD Million) TABLE 31 Canada market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 32 Canada market, by application, 2012 - 2022 (USD Million) TABLE 33 Europe market, by product, 2012 - 2022 (USD Million) TABLE 34 Europe market, by equipment, 2012 - 2022 (USD Million) TABLE 35 Europe market, by source, 2012 - 2022 (USD Million) TABLE 36 Europe market, by non mammalian source, 2012 - 2022 (USD Million) TABLE 37 Europe market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 38 Europe market, by application, 2012 - 2022 (USD Million) TABLE 39 UK market, by product, 2012 - 2022 (USD Million) TABLE 40 UK market, by equipment, 2012 - 2022 (USD Million) TABLE 41 UK market, by source, 2012 - 2022 (USD Million) TABLE 42 UK market, by non mammalian source, 2012 - 2022 (USD Million) TABLE 43 UK market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 44 UK market, by application, 2012 - 2022 (USD Million) TABLE 45 Germany market, by product, 2012 - 2022 (USD Million) TABLE 46 Germany market, by equipment, 2012 - 2022 (USD Million) TABLE 47 Germany market, by source, 2012 - 2022 (USD Million) TABLE 48 Germany market, by non mammalian source, 2012 - 2022 (USD Million) TABLE 49 Germany market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 50 Germany market, by application, 2012 - 2022 (USD Million) TABLE 51 Asia Pacific market, by product, 2012 - 2022 (USD Million) TABLE 52 Asia Pacific market, by equipment, 2012 - 2022 (USD Million) TABLE 53 Asia Pacific market, by source, 2012 - 2022 (USD Million) TABLE 54 Asia Pacific market, by non mammalian source, 2012 - 2022 (USD Million) TABLE 55 Asia Pacific market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 56 Asia Pacific market, by application, 2012 - 2022 (USD Million) TABLE 57 Japan market, by product, 2012 - 2022 (USD Million) TABLE 58 Japan market, by equipment, 2012 - 2022 (USD Million) TABLE 59 Japan market, by source, 2012 - 2022 (USD Million) TABLE 60 Japan market, by non mammalian source, 2012 - 2022 (USD Million) TABLE 61 Japan market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 62 Japan market, by application, 2012 - 2022 (USD Million) TABLE 63 China market, by product, 2012 - 2022 (USD Million) TABLE 64 China market, by equipment, 2012 - 2022 (USD Million)

TABLE 65 China market, by source, 2012 - 2022 (USD Million) TABLE 66 China market, by non mammalian source, 2012 - 2022 (USD Million) TABLE 67 China market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 68 China market, by application, 2012 - 2022 (USD Million) TABLE 69 India market, by product, 2012 - 2022 (USD Million) TABLE 70 India market, by equipment, 2012 - 2022 (USD Million) TABLE 71 India market, by source, 2012 - 2022 (USD Million) TABLE 72 India market, by non mammalian source, 2012 - 2022 (USD Million) TABLE 73 India market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 74 India market, by application, 2012 - 2022 (USD Million) TABLE 75 Latin America market, by product, 2012 - 2022 (USD Million) TABLE 76 Latin America market, by equipment, 2012 - 2022 (USD Million) TABLE 77 Latin America market, by source, 2012 - 2022 (USD Million) TABLE 78 Latin America market, by non mammalian source, 2012 - 2022 (USD Million) TABLE 79 Latin America market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 80 Latin America market, by application, 2012 - 2022 (USD Million) TABLE 81 Brazil market, by product, 2012 - 2022 (USD Million) TABLE 82 Brazil market, by equipment, 2012 - 2022 (USD Million) TABLE 83 Brazil market, by source, 2012 - 2022 (USD Million) TABLE 84 Brazil market, by non mammalian source, 2012 - 2022 (USD Million) TABLE 85 Brazil market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 86 Brazil market, by application, 2012 - 2022 (USD Million) TABLE 87 Mexico market, by product, 2012 - 2022 (USD Million) TABLE 88 Mexico market, by equipment, 2012 - 2022 (USD Million) TABLE 89 Mexico market, by source, 2012 - 2022 (USD Million) TABLE 90 Mexico market, by non mammalian source, 2012 - 2022 (USD Million) TABLE 91 Mexico market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 92 Mexico market, by application, 2012 - 2022 (USD Million) TABLE 93 MEA market, by product, 2012 - 2022 (USD Million) TABLE 94 MEA market, by equipment, 2012 - 2022 (USD Million) TABLE 95 MEA market, by source, 2012 - 2022 (USD Million) TABLE 96 MEA market, by non mammalian source, 2012 - 2022 (USD Million) TABLE 97 MEA market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 98 MEA market, by application, 2012 - 2022 (USD Million) TABLE 99 South Africa market, by product, 2012 - 2022 (USD Million) TABLE 100 South Africa market, by equipment, 2012 - 2022 (USD Million) TABLE 101 South Africa market, by source, 2012 - 2022 (USD Million) TABLE 102 South Africa market, by non mammalian source, 2012 - 2022 (USD Million) TABLE 103 South Africa market, by type of cell lines, 2012 - 2022 (USD Million) TABLE 104 South Africa market, by application, 2012 - 2022 (USD Million)

For More Information visit http://www.grandviewresearch.com/industry-analysis/cell-linedevelopment-market

List of Figures FIG. 1 Cell line development : Market segmentation FIG. 2 Global cell line development market, 2012 - 2022 (USD Million) FIG. 3 Cell line development: Market dynamics FIG. 4 Key opportunities prioritized FIG. 5 Cell line development market - Porterâ&#x20AC;&#x2122;s analysis FIG. 6 Cell line development company market share, 2014 FIG. 7 Other market players , 2014 FIG. 8 Cell line development market positioning, 2014 FIG. 9 Cell line development market - PESTEL analysis FIG. 10 Cell line development revenue share by product, 2014 & 2022 FIG. 11 Reagents and media market, 2012 - 2022 (USD Million) FIG. 12 Equipment market, 2012 - 2022 (USD Million) FIG. 13 Incubators market, 2012 - 2022 (USD Million) FIG. 14 Centrifuges market, 2012 - 2022 (USD Million) FIG. 15 Bioreactors market, 2012 - 2022 (USD Million) FIG. 16 Storage equipment market, 2012 - 2022 (USD Million) FIG. 17 Microscopes market, 2012 - 2022 (USD Million) FIG. 18 Accessories and consumables market, 2012 - 2022 (USD Million) FIG. 19 Cell line development revenue share by source, 2014 & 2022 FIG. 20 Mammalian cell line development market, 2012 - 2022 (USD Million) FIG. 21 Non mammalian cell line development market, 2012 - 2022 (USD Million) FIG. 22 Insects cell line development market, 2012 - 2022 (USD Million) FIG. 23 Amphibians cell line development market, 2012 - 2022 (USD Million) FIG. 24 Cell line development revenue share by type of cell lines, 2014 & 2022 FIG. 25 Recombinant cell line market, 2012 - 2022 (USD Million) FIG. 26 Hybridomas market, 2012 - 2022 (USD Million) FIG. 27 Continuous cell lines market, 2012 - 2022 (USD Million) FIG. 28 Primary cell lines market, 2012 - 2022 (USD Million) FIG. 29 Cell line development revenue share by application, 2014 & 2022 FIG. 30 Bioproduction market, 2012 - 2022 (USD Million) FIG. 31 Drug discovery market, 2012 - 2022 (USD Million) FIG. 32 Toxicity testing market, 2012 - 2022 (USD Million) FIG. 33 Tissue engineering market, 2012 - 2022 (USD Million) FIG. 34 Research market, 2012 - 2022 (USD Million) FIG. 35 Cell line development market share, by region, 2014 & 2022 FIG. 36 North America cell line development market, 2012 - 2022 (USD Million) FIG. 37 U.S. cell line development market, 2012 - 2022 (USD Million) FIG. 38 Canada cell line development market, 2012 - 2022 (USD Million) FIG. 39 Europe cell line development market, 2012 - 2022 (USD Million) FIG. 40 UK cell line development market, 2012 - 2022 (USD Million) FIG. 41 Germany cell line development market, 2012 - 2022 (USD million)

FIG. 42 Asia Pacific cell line development market, 2012 - 2022 (USD million) FIG. 43 Japan cell line development market, 2012 - 2022 (USD million) FIG. 44 China cell line development market, 2012 - 2022 (USD million) FIG. 45 India cell line development market, 2012 - 2022 (USD million) FIG. 46 Latin America cell line development market, 2012 - 2022 (USD million) FIG. 47 Brazil cell line development market, 2012 - 2022 (USD million) FIG. 48 Mexico cell line development market, 2012 - 2022 (USD million) FIG. 49 MEA cell line development market, 2012 - 2022 (USD million) FIG. 50 South Africa cell line development market, 2012 - 2022 (USD million)

Further key findings from the study suggest: 



Reagent and media was the largest product market in 2014, owing to increasing number of cell culture procedures. Reagent and media are necessary components involved in cell line development procedures & cell culture and are cost intensive in nature. The market for reagent and media was valued at over 1.0 billion in 2014. Mammalian cell lines were widely used as a source for cell line development in 2014, owing to associated advantages such as accurate complex protein expression nature, critical for the production of monoclonal antibodies, vaccines, and biologics. Cell line development finds the largest application in the bioproduction of biologics, vaccines, Mabs, therapeutic proteins and biosimilars. Rising demand for monoclonal antibodies and vaccines are expected to boost the growth of this segment over the forecast period. The market for cell line development based bioproduction is also expected to witness lucrative growth of over 12.5% during the forecast period. North America was the largest market in 2014, with revenue estimated at over 800 million. The region’s market dominance is attributed to factors such as the growing adoption rates of cell culture techniques, presence of well developed healthcare infrastructure, supportive government initiatives and high healthcare expenditure levels. Asia Pacific cell line development market is anticipated to register rapid growth over the forecast period owing to factors such as the presence of high unmet needs, rising number of CROs (Contract Research Organization) providing pertinent services, growing R&D investments aimed at the development of stable cell lines and increasing biologics production. Key players in this market include European Collection of cell Cultures (ECACC), Lonza Group AG, GE Healthcare, Thermo Fisher Scientific Inc., Sartorious AG, Selexis SA, Wuxi AppTec Inc., Sigma-Aldrich Corporation, American Type Culture Collection (ATCC) and Corning Inc.

Request free sample of this Report @ http://www.grandviewresearch.com/industryanalysis/cell-line-development-market/request

For the purpose of this study, Grand View Research has segmented the global cell line development market on the basis of product, source, type of cell line, application and region: Global Cell Line Development Product Outlook (Revenue, USD Million, 2012– 2022)  



Reagents and media Equipment  Incubators  Centrifuges  Bioreactors  Storage equipment  Microscopes Accessories and consumables

Global Cell Line Development Source Outlook (Revenue, USD Million, 2012– 2022) o o

Mammalian Non mammalian  Insects  Amphibians

Global Cell Line Development Type Of Cell Line Outlook (Revenue, USD Million, 2012– 2022)    

Recombinant cell lines Hybridomas Continuous cell line Primary cell lines

Global Cell Line Development Application Outlook (Revenue, USD Million, 2012– 2022)     

Bioproduction Drug discovery Toxicity testing Tissue engineering Research

Cell Line Development Regional Outlook (Revenue, USD Billion, 2014 – 2022) 



North America  U.S.  Canada Europe  Germany  UK



Browse

Asia Pacific  China  Japan  India Latin America  Mexico  Brazil MEA  South Africa

All

Reports

this